Phase Ia/Ib multicenter investigator initiated trial of Mogamulizumab for advanced or recurrent cancer. - Phase Ia/Ib multicenter investigator initiated trial of Mogamulizumab for advanced or recurrent cancer.

Aichi Medical University School of Medicine, Department of Tumor Immunology0 个研究点目标入组 58 人开始时间: 2013年2月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Patients with HIV antibody positive. (2) Patients with HCV antibody positive. (3) Patients with autoimmune disease. (4) Patients with HBs antigen or HBV-DNA positive. (5) History of serious anaphylaxis induced by antibody preparation. (6) Patients with double cancer. (7) Within 4 weeks after treatment with anticancer agent, immune suppressant, immune enhancer, cytokine therapy, radiotherapy or surgery for the primary disease. (8) Pregnant or breast-feeding females and females who have a possibility of pregnancy. (9) Patients with active infection. (10) Patients with psychosis or dementia. (11) Patients who need continuous systemic administration of adrenocorticosteroid. (12) Patients who have received hematopoietic stem cell transplantation. (13) Patients who have presence or suspicion of CNS involvement. (14) Patients who are administered the other investigational product within 4 weeks of the entry. (15) Patients treated with immunotherapy for cancer (e.g. cancer vaccine therapy) within 12 weeks of the entry. (16) Any other inadequacy for this study.

发起方

Aichi Medical University School of Medicine, Department of Tumor Immunology